Brief: Tenaya Therapeutics Q2 Loss Per Share $13.26
08/09/2021 21:11
Sept 8 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS REPORTS SECOND QUARTER 2021 FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATES
* Q2 LOSS PER SHARE $13.26
* TENAYA - EXPECTS CURRENT CASH, CASH EQUIVALENTS TO BE
ENOUGH TO
FUND ITS CURRENT OPERATING PLAN AT LEAST INTO H2 2023
* QTRLY LOSS PER SHARE $13.26
Source text for Eikon: ID:nBw9217tka
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027